Clinical Outcome and Fusion Results Using the SiJoin® Transfixing Sacroiliac Fusion Device

• Sponsor: VG Innovations, LLC (Industry)
• Overall Status: Enrolling by invitation
• CT.gov ID: NCT05712850
• Collaborator: (none)
• Enrollment: 25
• Location: 1
• Anticipated Duration (Months): 26.3
• Patients Per Site Per Month: 0.9

Study Details

Study Description

Brief Summary

The purpose of this clinical study is to evaluate fusion of the SI joint(s) and any reduction in VAS pain scores in a prospective cohort of patients utilizing the SiJoin® Transfixing Sacroiliac Fusion Device in patients that received sacroiliac fusion, without ancillary stabilization devices.

Condition or Disease	Intervention/Treatment	Phase
Degenerative Sacroiliitis, Inflammatory Sacroiliitis, Iatrogenic Instability, Osteitis Condensans Ilii, Pelvic Fracture	Procedure: VerteLoc

Detailed Description

Study Title: A prospective, single arm clinical trial evaluating clinical outcome and fusion results using the SiJoin® Transfixing Sacroiliac Fusion Device

Instrumentation SiJoin® Transfixing Sacroiliac Fusion Device Study Design: Non-randomized, prospective, single arm, single center clinical trial

Patient Population and Sample Size:

Patients (n≥25) from 1 clinical site, who have been medically evaluated, found appropriate for, and have agreed to treatment by sacroiliac joint fixation, including unilateral and/or bilateral sacroiliac fusion according to accepted medical standards using the SiJoin® Transfixing Sacroiliac Fusion Device.

Objectives: The primary objective of this study is:

1. Evaluate the fusion status of sacroiliac joints at 12 months (depending on patient (vailability) following joint fusion/fixation using the SiJoin® Transfixing Sacroiliac Fusion Device;

2. Subject success / Clinical outcome: Evaluate the reduction in baseline VAS back pain score at 2-3 weeks, 3 months, and 12 months.

The secondary objectives of this study are to:

1. Assess the ease of use of the SiJoin® Fusion System;

2. Document the occurrence of adverse events related or possibly related to the use of the SiJoin® Fusion System;

3. Document the occurrence of subsequent surgical intervention at the sacroiliac joint.

Inclusion Criteria:

Candidates must meet ALL of the following:

1. Have provided consent for research by signing the Information and Consent for Research form;

2. Have given appropriate operative consent for a sacroiliac joint fixation procedure as standard of care using the SiJoin® Transfixing Sacroiliac Fusion Device;

3. Are skeletally mature male or female, and are at least 18 years of age at time of surgery;

4. Patient history confirms sacroiliac joint disfunction;

5. Failure of six months of conservative care;

6. Failure of NSAIDs;

7. Positive diagnosis injection of sacroiliac joint; and

8. Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation.

Exclusion Criteria:

Candidates will be excluded if they have ANY of the following:

1. Previous surgery or prior hardware in place at the target sacroiliac joint;

2. Deidentified data cannot be provided;

3. If female, pregnant at time of sacroiliac joint surgery;

4. Found to be inappropriate candidate for sacroiliac joint fixation;

5. Requires additional and/or other surgical technique and/or approach to the sacroiliac joint, which may in the opinion of the Primary Investigator confound measurement of outcome variables;

6. Has a medical disorder or is receiving medications that would be expected to interfere with osteogenesis;

7. Has active malignancy, or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years or surgery;

8. Has active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results;

9. Has BMI >40%;

10. Has history of tobacco smoking within 6 months prior to operation;

11. Has history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study;

12. Has history of diabetes;

13. Are participating in any other clinical trial;

14. Patient is an employee (or family members of employees) of the PI/site or Sponsor; or

15. Patient is limited or non-reader (e.g., blind, illiterate) Study Duration: 12 months

Study Outcomes:

The primary study outcomes of this study are:

1. Fusion grade at 12 months follow-up (depending on patient availability) using CT scans with a grading system based on:

2. Complete fusion; or

3. No fusion.

4. Subject success / Clinical outcome: Evaluate the reduction in baseline VAS back pain score at:

5. 2-3 weeks;

6. 3 months; and

7. 12 months.

The secondary outcomes of this study are:

1. Surgeon opinion of "ease of use" utilizing the SiJoin® Fusion System (0-10);

2. Occurrence of adverse events related or possibly related to the use of the SiJoin® Fusion System; and

3. Occurrence of subsequent surgical intervention at the target joint.

Study Assessments

• Intraoperative: Post-placement radiograph;

• 12 month: sacroiliac joint CT scan;

• Patient provided VAS pain scores at pre-op, and each subsequent follow-up appointment.

Study Design

• Study Type: Observational
• Anticipated Enrollment: 25 participants
• Observational Model: Case-Control
• Time Perspective: Prospective
• Official Title: A Prospective, Single Arm Clinical Trial Evaluating Clinical Outcome and Fusion Results Using the SiJoin® Transfixing Sacroiliac Fusion Device
• Actual Study Start Date: Jan 19, 2023
• Anticipated Primary Completion Date: Jan 18, 2024
• Anticipated Study Completion Date: Mar 31, 2025

Outcome Measures

Primary Outcome Measures

1. Fusion Status/Evaluation [12 Months]

   Evaluate the fusion status of SI Joints using CT scans with a grading system based on: Complete fusion; or No fusion.

2. VAS Reduction [2-3 weeks, 3 Months, 6 Months, 12 Months]

   Composite endpoint of reduction from baseline in VAS back pain score by at least 2 points.

Secondary Outcome Measures

1. Ease of Use [12 months]

   Assess the ease of use of the SiJoin® Fusion System

2. Adverse Avents [12 months]

   Monitor the occurrence of adverse events related or possibly related to the use of the SiJoin® Fusion System;

3. Subsequent Surgical Interventions [12 months]

   Monitor the occurrence of subsequent surgical intervention at the target sacroiliac joint(s).

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 85 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. Have provided consent for research by signing the Information and Consent for research form;

2. Have given appropriate operative consent for a sacroiliac joint fixation procedure as standard of care using the SiJoin® Transfixing Sacroiliac Fusion Device;

3. Are skeletally mature male or female, and are at least 18 years of age at time of surgery;

4. Patient history confirms sacroiliac joint disfunction;

5. Failure of six months of conservative care;

6. Failure of NSAIDs;

7. Positive diagnosis injection of sacroiliac joint; and

8. Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation.

Exclusion Criteria:

1. Previous surgery or prior hardware in place at the target sacroiliac joint;

2. Deidentified data cannot be provided;

3. If female, pregnant at time of sacroiliac joint surgery;

4. Found to be inappropriate candidate for sacroiliac joint fixation;

5. Requires additional and/or other surgical technique and/or approach to the sacroiliac joint, which may in the opinion of the Primary Investigator confound measurement of outcome variables;

6. Has a medical disorder or is receiving medications that would be expected to interfere with osteogenesis;

7. Has active malignancy, or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years or surgery;

8. Has active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results;

9. Has BMI >40%;

10. Has history of tobacco smoking within 6 months prior to operation;

11. Has history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study;

12. Has history of diabetes;

13. Are participating in any other clinical trial;

14. Patient is an employee (or family members of employees) of the PI/site or Sponsor; or

15. Patient is limited or non-reader (e.g., blind, illiterate)

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Seaside Surgery Center	Naples	Florida	United States	34109

Sponsors and Collaborators

• VG Innovations, LLC

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: VG Innovations, LLC
• ClinicalTrials.gov Identifier: NCT05712850
• Other Study ID Numbers: VGI-004
• First Posted: Feb 6, 2023
• Last Update Posted: Feb 6, 2023
• Last Verified: Jan 1, 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Osteitis; Sacroiliitis; Hip Fractures

Study Results

No Results Posted as of Feb 6, 2023